Replimune reports Q3 FY2024 net loss $51.1M; cash $466.4M; RP1 BLA plan for 2H 2024

Replimune Group, Inc.

2024-Q3 EPS reported -$2.42

Net loss of $51.1M for Q3 FY2024, up from $39.7M in prior year; R&D expenses $42.8M vs $30.3M.
Cash, equivalents & short-term investments $466.4M as of Dec 31, 2023; cash runway extended into 2H 2026.
BLA submission for RP1 in anti-PD1 failed melanoma planned for 2H 2024; Phase 3 confirmatory trial to start 2H 2024.
RP2 data in uveal melanoma positive; planning for potential registrational trial in advanced uveal melanoma.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Replimune Group, Inc. reported financial results for third quarter ended December 31, 2023.

Period: third quarter ended December 31, 2023
Result: reported results

Exact text from the filing

On February 8, 2024, Replimune Group, Inc. (the “Company”) issued a news release announcing its financial results for the third quarter ended December 31, 2023 and certain corporate updates.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Replimune Group, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-011951

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.